photo pending
B7-33 is a synthetic single-chain peptide derived from the B-chain of human relaxin-2. While broader research has examined its interaction with relaxin family peptide receptor 1 (RXFP1), a more specific area of investigation concerns the molecular and structural changes that occur in cardiac tissue following experimental injury.
B7-33 has been employed as an experimental ligand in preclinical research to study cellular stress, extracellular matrix alterations, cardiac remodeling, and receptor-associated signaling. These findings provide useful models for examining the connections between cardiac tissue biology and RXFP1-related pathways. They don't show human therapeutic applications or clinical efficacy.
What Is Cardiac Remodeling?
The structural, cellular, and molecular alterations that can take place in heart tissue in reaction to changed physiological or experimental circumstances are referred to as cardiac remodeling.
Cardiac remodeling refers to structural, cellular,, and molecular changes that can occur in heart tissue in response to altered physiological or experimental conditions.
Researchers studying remodeling may measure changes in cardiomyocytes, fibroblasts, extracellular matrix composition, and ventricular structure. Collagen is particularly important because it is a major structural element of the cardiac extracellular matrix.
Excessive extracellular matrix deposition is generally described as fibrosis. In laboratory cardiac models, collagen staining, collagen concentration and expression of matrix-associated proteins can therefore be used as measurable experimental endpoints.
B7-33 has been incorporated into these models to investigate how activation of RXFP1-associated pathways relates to these processes.
B7-33 and Experimental Models of Cardiac Fibrosis
One of the principal cardiac research areas involving B7-33 concerns extracellular matrix regulation.
Experiments using models of myocardial damage and isoproterenol-induced cardiac fibrosis were reported in the first characterisation of B7-33. Endpoints such as total collagen concentration and left ventricular collagen deposition were measured by the researchers. These investigations showed quantifiable changes between the control and B7-33-exposed groups.
A later study published in Biomedicine & Pharmacotherapy used an isoprenaline-induced cardiomyopathy model to examine several cardiac parameters. These included left ventricular fibrosis, inflammation, cardiomyocyte hypertrophy, vascular density, and aortic contractility. B7-33, relaxin-2, and perindopril were evaluated as separate experimental conditions.
For research purposes, these studies are useful because they demonstrate how B7-33 can be incorporated into controlled models in which extracellular matrix and cardiac structural variables can be quantified.
Investigating Cardiomyocytes and Cellular Stress
Extracellular matrix measures are not the only focus of cardiac B7-33 research.
A 2020 study investigated B7-33 in isolated primary cardiomyocytes exposed to simulated ischaemia-reoxygenation and in a rat model of cardiac ischaemia-reperfusion. Along with cellular and molecular goals, the researchers evaluated heart characteristics.
One molecular marker examined was glucose-regulated protein 78 (GRP78), which is associated with endoplasmic reticulum stress and the unfolded protein response.
The experiments also investigated extracellular signal-regulated kinase 1/2 (ERK1/2). Changes observed following experimental manipulation of this pathway provided evidence for an association between B7-33-related signaling and cellular stress responses in the model.
Because the work links a receptor-associated signaling cascade with quantifiable intracellular endpoints rather than only looking at heart anatomy, it is very pertinent to molecular cardiac research.
Why ERK1/2 Is an Important Experimental Endpoint
B7-33 has been characterized as a functionally selective RXFP1 agonist. Functional selectivity refers to the capability of a ligand to favor particular signaling responses associated with a receptor rather than reproducing every signaling response produced by another ligand.
Experimental characterization of B7-33 identified preferential ERK1/2-associated signaling. Research has also connected RXFP1-related signaling with matrix metalloproteinase-2 (MMP-2), an enzyme involved in extracellular matrix turnover.
Consequently, ERK1/2 phosphorylation and MMP activity provide researchers with quantifiable biochemical endpoints for investigating how receptor activation relates to changes elsewhere in the experimental system.
What Can Researchers Measure in B7-33 Cardiac Studies?
Researchers can measure collagen accumulation, extracellular matrix proteins, ventricular parameters, cellular stress markers such as GRP78, and changes in ERK1/2 signalling in experimental B7-33 cardiac studies.
Published B7-33 research illustrates the range of techniques that can be combined when investigating cardiac remodeling.
Histological staining can quantify collagen accumulation within tissue sections. Biochemical measurements can assess total collagen concentration or matrix-associated proteins. Echocardiographic measurements have been incorporated into preclinical experimental designs to characterize changes in ventricular parameters, while cultured cardiomyocytes enable investigation of specific intracellular responses under controlled conditions.
Molecular assays can additionally measure proteins such as GRP78 or changes in ERK1/2 phosphorylation.
Together, these approaches allow B7-33 research to be considered at several experimental levels: receptor signaling, intracellular responses, extracellular matrix composition, and tissue-level remodeling.
Current Limits of B7-33 Cardiac Remodeling Research
An important distinction is that the published findings discussed above come primarily from cellular and preclinical experimental systems.
These studies can identify associations between B7-33 exposure, RXFP1-associated signaling and measurable cardiac endpoints, but they should not be interpreted as evidence that B7-33 prevents, treats or manages cardiovascular disease in humans.
Instead, the research that is now accessible defines B7-33 as an experimental chemical for examining particular facets of cellular stress, remodeling, cardiac extracellular matrix biology, and RXFP1 pharmacology.
To better describe these mechanisms and determine how findings differ amongst experimental models, more study is needed.
Frequently Asked Questions About B7-33
B7-33 interacts with RXFP1-associated signaling, while relaxin biology has been linked to extracellular matrix regulation. Researchers have therefore used B7-33 in controlled cardiac models to investigate collagen deposition, cellular signaling, and other measurable features of tissue remodeling.
Increased extracellular matrix component accumulation, especially collagen, within heart tissue is referred to as cardiac fibrosis. Fibrosis can be measured by researchers utilizing methods including biochemical tests of collagen and histology collagen staining.
Endpoints such as collagen content, ERK1/2 signaling, GRP78 expression, and other indicators linked to cellular stress and extracellular matrix modulation have been evaluated in published investigations. Depending on the experimental model, the precise endpoints are determined.
GRP78 is a molecular chaperone associated with the endoplasmic reticulum stress response. Researchers have measured GRP78 expression in experimental cardiomyocyte models to investigate cellular responses associated with B7-33 and ERK1/2 signaling.
Indeed. Both whole-animal experimental models and isolated primary cardiomyocytes have been used in published studies. Researchers can study intracellular signaling and molecular markers in more controlled experimental settings with cell-based technologies.
No. The research discussed here is primarily preclinical and does not establish B7-33 as a treatment for cardiovascular disease or demonstrate clinical efficacy in humans. B7-33 should be discussed in this context as an experimental research compound.
Scientific references
- 1 Hossain MA, et al. A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1. Sci Rep. 2016;6:17733. https://pmc.ncbi.nlm.nih.gov/articles/PMC6013806/
- 2 Devarakonda T, Mauro AG, Guzman G, et al. B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice. J Am Heart Assoc. 2020;9(8):e015748. doi:10.1161/JAHA.119.01574 https://pubmed.ncbi.nlm.nih.gov/32295457/
- 3 Alam F, Gaspari TA, Kemp-Harper BK, et al. The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy. Biomed Pharmacother. 2023;160:114370. doi:10.1016/j.biopha.2023.114370. https://pubmed.ncbi.nlm.nih.gov/36753958/
- 4 Praveen P, Kocan M, Valkovic A, Bathgate RAD, Hossain MA. Single chain peptide agonists of relaxin receptors. Mol Cell Endocrinol. 2019;487:34–39. doi:10.1016/j.mce.2019.01.008. https://pubmed.ncbi.nlm.nih.gov/30641102/
- 5 Praveen P, et al. Further Developments towards a Minimal Potent Derivative of Human Relaxin-2. Published research examining B7-33 and the development of simplified relaxin-2-derived peptide scaffolds. https://pubmed.ncbi.nlm.nih.gov/37628851/
Research-use disclaimer: For research and laboratory use only. Not for human or animal consumption.